SOPHiA GENETICS (SOPH) EBITDA (2020 - 2025)

SOPHiA GENETICS has disclosed EBITDA across 6 years of filings, most recently posting -$18.5 million for Q4 2025.

• EBITDA for Q4 2025 came in at -$18.5 million, down 104.57% year-over-year; the trailing twelve-month figure through Dec 2025 was -$70.9 million (down 21.88% YoY), and the FY2025 annual result was -$70.9 million, down 76.48% from the prior year.
• EBITDA came in at -$18.5 million for Q4 2025 at SOPHiA GENETICS, down from -$17.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.1 million in Q4 2024 to a low of -$20502.0 billion in Q3 2021.
• The 5-year median for EBITDA is -$18.2 million (2025), against an average of -$1025.1 billion.
• Across the five-year window, EBITDA sank 217389460190.53% in 2021 and jumped 100.0% in 2022, its largest moves.
• SOPHiA GENETICS's EBITDA stood at -$21.0 million in 2021, then rose by 28.21% to -$15.1 million in 2022, then rose by 19.47% to -$12.1 million in 2023, then gained by 25.49% to -$9.1 million in 2024, then slumped by 104.57% to -$18.5 million in 2025.
• The last three EBITDA figures came in at -$18.5 million (Q4 2025), -$17.9 million (Q3 2025), and -$18.5 million (Q2 2025), per Business Quant data.